Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease.

AIMS To evaluate the role of plasma lipids in recurrent vascular events, including stroke, among individuals with established cerebrovascular disease. METHODS AND RESULTS Plasma total cholesterol, HDL cholesterol, and triglycerides were measured at baseline among individuals participating in the Perindopril Protection Against Recurrent Stroke (PROGRESS) study, a randomized clinical trial of blood pressure lowering among patients with previous stroke or transient ischaemic attack. A series of nested case-control studies were used to investigate the association between each of these lipid variables and the risk of subsequent haemorrhagic stroke, ischaemic stroke, myocardial infarction (MI), and heart failure. A total of 895 patients were selected as cases (83 haemorrhagic stroke, 472 ischaemic stroke, 206 MI, and 258 heart failure) and each was matched with one to three controls. After adjustment for other major cardiovascular risk factors, none of the lipid variables was associated with the risk of either stroke subtype. There were significant positive and negative associations for total cholesterol and HDL, respectively, with the risk of MI; the odds ratio comparing the highest and lowest thirds of each of these lipid variables was 2.00 (95% CI: 1.30-3.09) for total cholesterol and 0.58 (95% CI: 0.37-0.90) for HDL. HDL was inversely associated with the risk of heart failure; however, this result was of borderline statistical significance (P=0.05). CONCLUSION Lipid variables are associated with the risk of MI, but not recurrent stroke, in patients with established cerebrovascular disease.

[1]  R. Collins,et al.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.

[2]  C. Anderson,et al.  Ten-Year Risk of First Recurrent Stroke and Disability After First-Ever Stroke in the Perth Community Stroke Study , 2004, Stroke.

[3]  Progress.  Effects of a Perindopril-Based Blood Pressure–Lowering Regimen on Disability and Dependency in 6105 Patients With Cerebrovascular Disease A Randomized Controlled Trial , 2003 .

[4]  M. Hennerici,et al.  Design and Baseline Characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study , 2003, Cerebrovascular Diseases.

[5]  Mark Woodward,et al.  Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. , 2003, International journal of epidemiology.

[6]  M. Woodward,et al.  Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. , 2003, European heart journal.

[7]  Konrad Jamrozik,et al.  Long-Term Disability After First-Ever Stroke and Related Prognostic Factors in the Perth Community Stroke Study, 1989–1990 , 2002, Stroke.

[8]  H. Tunstall-Pedoe,et al.  The prevalence of treatable left ventricular systolic dysfunction in patients who present with noncardiac vascular episodes: a case-control study. , 2002, Journal of the American College of Cardiology.

[9]  R. D'Agostino,et al.  Risk of Hospitalized Stroke in Men Enrolled in the Honolulu Heart Program and the Framingham Study: A Comparison of Incidence and Risk Factor Effects , 2002, Stroke.

[10]  R. Sacco,et al.  Mortality and causes of death after first ischemic stroke , 2001, Neurology.

[11]  R. Sacco,et al.  Mortality and causes of death after first ischemic stroke: The Northern Manhattan Stroke Study , 2001 .

[12]  D. Johnston.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack , 2001, The Lancet.

[13]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[14]  J. Egido,et al.  Neurosonology in Cerebral Ischemia: Future Application of Transcranial Doppler in Acute Stroke , 2001, Cerebrovascular Diseases.

[15]  B. Davis,et al.  Reduction of Stroke Events With Pravastatin: The Prospective Pravastatin Pooling (PPP) Project , 2001, Circulation.

[16]  S. Ebrahim,et al.  HDL-Cholesterol, total cholesterol, and the risk of stroke in middle-aged British men. , 2000, Stroke.

[17]  D. Albanes,et al.  Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. , 1999, Stroke.

[18]  R. Collins,et al.  Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. , 1999, American journal of epidemiology.

[19]  Mark Woodward,et al.  Epidemiology: Study Design and Data Analysis , 1999 .

[20]  D. Jacobs,et al.  Low total serum cholesterol and intracerebral hemorrhagic stroke: is the association confined to elderly men? The Kaiser Permanente Medical Care Program. , 1996, Stroke.

[21]  L. Hansson.  Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS , 1996, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[22]  G. Boysen,et al.  Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen city heart study , 1994, BMJ.

[23]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[24]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.

[25]  D. Reed,et al.  Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. , 1989, Stroke.

[26]  D. Jacobs,et al.  Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. , 1989, The New England journal of medicine.

[27]  Simon Davies,et al.  Epidemiology: Study Design and Data Analysis (2nd ed.) , 2006 .

[28]  M. Woodward,et al.  The Asia Pacific Cohort Studies Collaboration , 2003 .

[29]  J. Chalmers.  Perindopril Protection Against Recurrent Stroke Study (PROGRESS) , 2001 .

[30]  R. Hirsch,et al.  Stroke in China (Sino-MONICA-Beijing study) 1984-1986. , 1992, Neuroepidemiology.

[31]  G. Moneta.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions Heart , 2022 .